SETTING: The incidence of multi- and extensively drug-resistant TB cases is increasing in many countries. Resistance to rifampicin is widely considered a surrogate marker for multiple drug resistant TB. No efforts have been made to identify and quantify the drug-resistant genotypes in the Syrian and Lebanese communities. OBJECTIVE: The genotypic characterization of rpo B mutations in the rifampicin drug-resistance region (RRDR) of resistant Mycobacterium tuberculosis isolates in Syrian and Lebanese patients. DESIGN: The pyrosequencing technique was applied to DNA derived from the M. tuberculosis isolates of 56 patients. RESULTS: RRDR sequencing identified 97 modified codons representing 35 different mutations; 31 (34%) of the 97 modifications were novel and have not been previously reported. The changes were mostly within codons 531 (37/97: 38%), 533 (28/97: 29%) and 526 (9/97: 9%). Additionally, 30 (54%) isolates had multiple codon changes. CONCLUSION: This study indicates the importance of the RRDR hotspot region for the detection of rifampicin resistance in MTB clinical isolates from Syrian and Lebanese patients. However, new mutations and mutations in other locations within the RRDR were also observed. The vast majority (95%) of the studied isolates from this pool of patients contained mutations in codons 531 and/or 533.
SETTING: The incidence of multi- and extensively drug-resistant TB cases is increasing in many countries. Resistance to rifampicin is widely considered a surrogate marker for multiple drug resistant TB. No efforts have been made to identify and quantify the drug-resistant genotypes in the Syrian and Lebanese communities. OBJECTIVE: The genotypic characterization of rpo B mutations in the rifampicin drug-resistance region (RRDR) of resistant Mycobacterium tuberculosis isolates in Syrian and Lebanese patients. DESIGN: The pyrosequencing technique was applied to DNA derived from the M. tuberculosis isolates of 56 patients. RESULTS: RRDR sequencing identified 97 modified codons representing 35 different mutations; 31 (34%) of the 97 modifications were novel and have not been previously reported. The changes were mostly within codons 531 (37/97: 38%), 533 (28/97: 29%) and 526 (9/97: 9%). Additionally, 30 (54%) isolates had multiple codon changes. CONCLUSION: This study indicates the importance of the RRDR hotspot region for the detection of rifampicin resistance in MTB clinical isolates from Syrian and Lebanese patients. However, new mutations and mutations in other locations within the RRDR were also observed. The vast majority (95%) of the studied isolates from this pool of patients contained mutations in codons 531 and/or 533.
Authors: Karol Gliniewicz; Mark Wildung; Lisa H Orfe; Gregory D Wiens; Kenneth D Cain; Kevin K Lahmers; Kevin R Snekvik; Douglas R Call Journal: BMC Microbiol Date: 2015-09-16 Impact factor: 3.605
Authors: Douglas L Huseby; Gerrit Brandis; Lisa Praski Alzrigat; Diarmaid Hughes Journal: Proc Natl Acad Sci U S A Date: 2020-01-28 Impact factor: 11.205
Authors: Eunjin Cho; Su Jin Lee; Jiyoung Lim; Dong Sik Kim; Namil Kim; Han Oh Park; Ji-Im Lee; Eunsoon Son; Sang Nae Cho; Wah Wah Aung; Jong Seok Lee Journal: J Clin Tuberc Other Mycobact Dis Date: 2022-02-09